肝细胞癌组织中微小RNA-552、微小RNA-383的表达及其对患者术后5年不良预后结局的影响

摘要
图/表
参考文献(21)
相关文章 (15)

全文: PDF (0 KB) HTML (44 KB)
输出: BibTeX | EndNote (RIS)

摘要目的检测微小RNA-552（miR-552）、微小RNA-383（miR-383）在肝细胞癌（HCC）组织中的表达情况，探讨miR-552 与miR-383 对HCC 患者预后的影响。方法选取2011年2月—2014年2月于广州市花都区人民医院住院并行根治性切除术的68 例HCC 患者，取患者的HCC 组织作为研究样本，取患者的癌旁正常组织（距肿瘤边缘>5 cm）作为对照样本。采用实时荧光定量聚合酶链反应（qRT-PCR）方法检测miR-552、miR-383 的相对表达量；分别按HCC 患者癌组织的miR-552、miR-383 相对表达量高低，将其分为miR-552 低表达组（miR-552 相对表达量<1.28，n=26）、miR-552 高表达组（miR-552 相对表达量>1.28，n=42）、miR-383 低表达组（miR-383 相对表达量<0.83，n=29）、miR-383 高表达组（miR-383 相对表达量>0.83，n=39）；χ2 检验分析HCC 组织中miR-552、miR-383 表达与患者临床病理特征的关系；Kaplan-Meier 生存曲线分析影响HCC 术后预后的因素；COX 回归分析影响HCC 术后5年预后结局的因素。结果 HCC 组织中miR-552 相对表达量高于癌旁正常组织，差异有统计学意义（P<0.05），miR-383 相对表达量低于癌旁正常组织，差异有统计学意义（P<0.05）；miR-552 低表达组与miR-552高表达组患者的年龄、性别、肝硬化比例比较，差异无统计学意义（P>0.05）；miR-552 低表达组患者的组织高分化、肿瘤直径≥5 cm、发生淋巴结转移、发生远处转移、TNM 分期Ⅲ～Ⅳ期、发生血管侵袭比例均低于miR-552高表达组，差异有统计学意义（P<0.05）；miR-383 低表达组与miR-383 高表达组患者的年龄、性别、肝硬化、发生远处转移、发生血管侵袭比例比较，差异无统计学意义（P>0.05）；miR-383 低表达组患者的组织高分化、肿瘤直径≥5 cm、发生淋巴结转移、TNM 分期Ⅲ～Ⅳ期比例高于miR-383 高表达组，差异有统计学意义（P<0.05）；miR-552低表达组患者的5年生存率高于miR-552 高表达组，差异有统计学意义（P<0.05）；miR-383 低表达组患者的5年生存率低于miR-383 高表达组，差异有统计学意义（P<0.05）；miR-552 高表达是影响患者术后5年不良预后结局的独立危险因素（β=0.558，HR=1.748，95%CI=1.065～2.870，P<0.05）；miR-383 高表达是影响患者术后5年不良预后结局的独立保护因素（β=-0.458，HR=0.634，95%CI=0.467～0.861，P<0.05）。结论 HCC 组织中miR-552、miR-383 表达分别升高、降低，二者与HCC 患者的5年生存率相关，对患者预后判断可能具有一定的价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	赵娟
	李辉
	徐沛演
	张成芳
	杜利军
	曹天生

关键词 ：肝细胞癌, 微小RNA-552, 微小RNA-383, 预后

Abstract：Objective To detect the expression of microRNA-552 (miR-552) and microRNA-383 (miR-383) in hepatocellular carcinoma (HCC) and to investigate the effect of miR-552 and miR-383 on the prognosis of HCC patients.Methods From February 2011 to February 2014, 68 patients with HCC who were hospitalized and underwent radical resection in Huadu District People′s Hospital of Guangzhou City were selected, the HCC tissue of the patients was taken as the study sample, and the adjacent normal tissue(more than 5 cm from the edge of the tumor) was taken as the control sample, the relative expression of miR-552 and miR-383 was detected by real-time fluorescent quantitative polymerase chain reaction (qRT-PCR). According to the relative expression of miR-552 and miR-383 in HCC tissues, the patients were divided into miR-552 low expression group (miR-552 relative expression <1.28, n=26), miR-552 high expression group (miR-552 relative expression >1.28, n=42), miR-383 low expression group (miR-383 relative expression <0.83, n=29) and miR-383 high expression group (miR-383 relative expression >0.83, n=39). χ2 test was used to analyze the relationship between the expression of miR-552 and miR-383 and the clinicopathological characteristics of HCC. Kaplan-Meier survival curve was used to analyze the factors influencing the prognosis of HCC, and COX regression was used to analyze the factors influencing the 5-year postoperative outcome of HCC. Results The relative expression of miR-552 in HCC tissues was higher than that in adjacent normal tissues, the difference was statistically significant (P<0.05), the relative expression of miR-383 was lower than that in adjacent normal tissues, the difference was statistically significant (P<0.05); comparison of age, gender, the proportion of liver cirrhosis between miR-552 high expression group and miR-552 low expression group, the differences were not statistically significant (P>0.05), while the proportions of high differentiation, tumor diameter ≥5 cm, lymph node metastasis, distant metastasis, TNM stage Ⅲ-Ⅳand vascular invasion in miR-552 low expression group were lower than those in miR-552 high expression group, the differences were statistically significant(P<0.05); comparison of age, gender, proportions of liver cirrhosis, distant metastasis and vascular invasion between miR-383 low expression group and miR-383 high expression group, the differences were not statistically significant (P>0.05), while the proportions of high differentiation, tumor diameter ≥5 cm, lymph node metastasis and TNM stage Ⅲ-Ⅳin miR-383 low expression group were higher than those in miR-383 high expression group, the differences were statistically significant (P<0.05);the 5-year survival rate of miR-552 low expression group was higher than that of miR-552 high expression group, the difference was statistically significant (P<0.05), and the 5-year survival rate of miR-383 low expression group was lower than that of miR-383 high expression group, the difference was statistically significant(P<0.05). The high expression of miR-552 was an independent risk factor for poor prognosis 5 years after surgery (β=0.558, HR=1.748, 95%CI=1.065-2.870, P<0.05). The high expression of miR-383 was an independent protective factor for the poor prognosis 5 years after surgery (β=-0.458, HR=0.634, 95%CI=0.467-0.861, P<0.05). Conclusion The expression of miR-552 and miR-383 in HCC is increased and decreased respectively, both of them are significantly related to 5-year survival rate of HCC patients, which may have some value in judging the prognosis of HCC patients.

Key words： Hepatocellular carcinoma microRNA-552 microRNA-383 Prognosis

基金资助:广东省广州市科技计划项目（202002030044）；广东省广州市花都区人民医院院内科研基金项目（2020B03）

作者简介: 赵娟（1984-）女，湖南永州人，硕士，副主任技师，研究方向：优生优育、遗传病诊断，肿瘤遗传等

引用本文:

赵娟; 李辉; 徐沛演;张成芳;杜利军;曹天生. 肝细胞癌组织中微小RNA-552、微小RNA-383的表达及其对患者术后5年不良预后结局的影响[J]. 中国当代医药, 2021, 28(21): 23-28.
ZHAO Juan; LI Hui; XU Pei-yan2;ZHANG Cheng-fang;DU Li-jun;CAO Tian-sheng. Expression of microRNA-552 and microRNA-383 in hepatocellular carcinoma and their influence on 5-year poor prognostic outcome. 中国当代医药, 2021, 28(21): 23-28.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I21/23

[1]	Tang A，Hallouch O，Chernyak V，et al.Epidemiology of hepatocellular carcinoma：target population for surveillance and diagnosis[J].Abdom Radiol（NY)，2018，43（1）：13-25.
[2]	黄风玲，杨颖，张瑞丽，等.肝细胞癌组织中高尔基体蛋白73 和转化生长因子β1 及Smad2 的表达水平及其意义[J].中国全科医学，2016，19（26）：3191-3195.
[3]	Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015[J].CA Cancer J Clin，2016，66（2）：115-132.
[4]	王珏，张婷婷，毛志远，等.肝细胞癌根治性切除术后预后因素分析[J].现代生物医学进展，2016，16（4）：101-194.
[5]	吴文涌，孟翔凌，齐勇，等.人肝细胞癌中LC3B 和p62 的表达及意义[J].临床与实验病理学杂志，2016，32（4）：366-369.
[6]	Catela Ivkovic T，Voss G，Cornella H，et al.MicroRNAs as cancer therapeutics：a step closer to clinical application[J].Cancer Lett，2017，407（1）：113-122.
[7]	李天雄，孙志鹏，尹刚，等.miR-133a-3p 通过抑制氧化还原因子1 抑制肝癌细胞恶性生物学行为[J].中国免疫学杂志，2020，36（10）：1217-1223.
[8]	洪嵩，蔡东峰，张靖，等.miR-552 靶向调控Wnt 抑制因子-1 促进MG-63 骨肉瘤细胞增殖、侵袭、迁移的实验研究[J].临床肿瘤学杂志，2019，24（6）：494-499.
[9]	Shang Y，Zang A，Li J，et al.MicroRNA-383 is a tumor suppressor and potential prognostic biomarker in human nonsmall cell lung caner[J].Biomed Pharmacother，2016，83（1）：1175-1181.
[10]	Sparks R，Madabhushi A.Statistical shape model for manifold regularization：gleason grading of prostate histology[J].Comput Vis Image Underst，2013，117（9）：1138-1146.
[11]	Greene FL，Page DL，Fleming ID，et al.AJCC cancer staging manual：American Joint Committee on Cancer[M].6thedn.Springer：New York，2002：131-138.
[12]	Rich N，Singal AG.Hepatocellular carcinoma tumour markers：current role and expectations[J].Best Pract Res Clin Gastroenterol，2014，28（5）：843-853.
[13]	付志豪，陈海明，王亚东，等.射频消融联合索拉菲尼治疗中晚期肝细胞癌的疗效及预后影响因素[J].重庆医学，2020，49（5）：714-717.
[14]	赵明英，李春林.血清YKL-40 联合AFP 在肝细胞癌手术患者中的水平及其对预后状况的影响[J].肝胆外科杂志，2019，27（5）：341-343，395.
[15]	倪卓然，谢坤，赵红川，等.肝细胞癌组织中Shh、Gli1、Snail、E-cadherin 表达的临床研究[J].安徽医科大学学报，2016，51（4）：536-540.
[16]	胡婧怡，周华邦，刘文迪，等.肝内胆管细胞癌与肝细胞癌临床特征及预后的比较研究[J].中华肝脏病杂志，2019，27（7）：511-515.
[18]	王磊，师国珍.miR-198 在肝细胞癌组织中的表达[J].中华实用诊断与治疗杂志，2019，33（9）：904-906.
[17]	Vasuri F，Visani M，Acquaviva G，et al.Role of microRNAs in the main molecular pathways of hepatocellular carcinoma[J].World J Gastroenterol，2018，24（25）：2647-2660.
[19]	WangJ，LiH，WangY，etal.MicroRNA-552enhancesmetastatic capacity of colorectal cancer cells by targeting a disintegrin and metalloprotease 28[J].Oncotarget，2016，7（43）：70 194-70 210.
[20]	Liu J，Dou Y，Sheng M.Inhibition of microRNA-383 has tumor suppressive effect in human epithelial ovarian cancer through the action on caspase-2 gene[J].Biomed Pharmacother，2016，83（1）：1286-1294.
[21]	Ma H，Liu B，Wang S，et al.MicroRNA-383 is a tumor suppressor in human lung cancer by targeting endothelial PAS domain-containing protein 1：MicroRNA-383 is a tumor suppressor in human lung cancer[J].Cell Biochem Funct，2016，34（8）：613-619.